Fox Run Management L.L.C. bought a new position in Alder BioPharmaceuticals, Inc. (NASDAQ:ALDR) during the second quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund bought 35,100 shares of the biopharmaceutical company’s stock, valued at approximately $402,000.

Other hedge funds also recently added to or reduced their stakes in the company. Nuveen Asset Management LLC boosted its stake in Alder BioPharmaceuticals by 36.6% in the first quarter. Nuveen Asset Management LLC now owns 66,224 shares of the biopharmaceutical company’s stock worth $1,377,000 after buying an additional 17,760 shares in the last quarter. Janus Capital Management LLC boosted its stake in Alder BioPharmaceuticals by 4.7% in the first quarter. Janus Capital Management LLC now owns 5,167,085 shares of the biopharmaceutical company’s stock worth $107,473,000 after buying an additional 230,044 shares in the last quarter. Credit Suisse AG boosted its stake in Alder BioPharmaceuticals by 19.8% in the first quarter. Credit Suisse AG now owns 243,807 shares of the biopharmaceutical company’s stock worth $5,071,000 after buying an additional 40,260 shares in the last quarter. Redmile Group LLC boosted its stake in Alder BioPharmaceuticals by 107.5% in the first quarter. Redmile Group LLC now owns 1,909,886 shares of the biopharmaceutical company’s stock worth $39,726,000 after buying an additional 989,336 shares in the last quarter. Finally, Endurant Capital Management LP bought a new stake in Alder BioPharmaceuticals during the first quarter worth approximately $763,000.

Alder BioPharmaceuticals, Inc. (ALDR) opened at 11.85 on Tuesday. Alder BioPharmaceuticals, Inc. has a one year low of $10.05 and a one year high of $36.48. The stock has a 50 day moving average of $17.14 and a 200 day moving average of $20.51. The firm’s market capitalization is $597.36 million.

Alder BioPharmaceuticals (NASDAQ:ALDR) last released its earnings results on Thursday, April 27th. The biopharmaceutical company reported ($1.99) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.95) by $1.04. During the same quarter in the previous year, the firm posted ($0.76) EPS. Analysts forecast that Alder BioPharmaceuticals, Inc. will post ($6.27) earnings per share for the current year.

COPYRIGHT VIOLATION NOTICE: This piece of content was first published by Daily Political and is the property of of Daily Political. If you are viewing this piece of content on another domain, it was copied illegally and reposted in violation of US & international copyright & trademark laws. The legal version of this piece of content can be viewed at https://www.dailypolitical.com/2017/07/18/35100-shares-in-alder-biopharmaceuticals-inc-aldr-acquired-by-fox-run-management-l-l-c.html.

Several analysts recently issued reports on the stock. Needham & Company LLC set a $36.00 price objective on shares of Alder BioPharmaceuticals and gave the company a “buy” rating in a research note on Monday. Zacks Investment Research raised shares of Alder BioPharmaceuticals from a “hold” rating to a “buy” rating and set a $13.00 price objective for the company in a research note on Tuesday, July 11th. Aegis reaffirmed a “buy” rating and set a $41.00 price objective on shares of Alder BioPharmaceuticals in a research note on Wednesday, July 5th. ValuEngine cut shares of Alder BioPharmaceuticals from a “sell” rating to a “strong sell” rating in a research note on Thursday, June 29th. Finally, Wells Fargo & Company reaffirmed an “outperform” rating and set a $51.00 price objective on shares of Alder BioPharmaceuticals in a research note on Wednesday, June 28th. Two equities research analysts have rated the stock with a sell rating, one has assigned a hold rating and ten have assigned a buy rating to the company. The company presently has a consensus rating of “Buy” and an average price target of $35.00.

About Alder BioPharmaceuticals

Alder BioPharmaceuticals, Inc, is a clinical-stage biopharmaceutical company that discovers, develops and seeks to commercialize genetically engineered therapeutic antibodies with the potential to meaningfully transform current treatment paradigms. Alder’s lead pivotal-stage product candidate, eptinezumab, is being evaluated for migraine prevention.

Want to see what other hedge funds are holding ALDR? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Alder BioPharmaceuticals, Inc. (NASDAQ:ALDR).

Institutional Ownership by Quarter for Alder BioPharmaceuticals (NASDAQ:ALDR)

Receive News & Ratings for Alder BioPharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Alder BioPharmaceuticals Inc. and related companies with MarketBeat.com's FREE daily email newsletter.